liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: Global relevance
Institute for Pharmacological Research, Mario Negri, Milan.
Stockholm County Council.
Linköping University, Department of Medicine and Health Sciences, Pharmacology . Linköping University, Faculty of Health Sciences.
Nordic School of Public Health.
Show others and affiliations
2009 (English)In: Expert Review of Pharmacoeconomics and Outcomes Research, ISSN 1473-7167, Vol. 9, no 1, 65-83 p.Article in journal (Refereed) Published
Abstract [en]

It is a continual challenge trying to improve the quality of prescribing while concurrently trying to address increasing pharmaceutical development, utilization and expenditure. National and regional reforms and initiatives in Sweden have moderated growth in ambulatory drug expenditure to 2.7% per annum in recent years despite increasing volumes. National reforms include mandatory generic substitution and value-based pricing alongside devolution of drug budgets to the regions. Regional initiatives include strengthening the role of the regional Drug and Therapeutic Committees, further budget devolution as well as strategies incorporating prescribing guidance and monitoring coupled with financial incentives. The extent and nature of the regional initiatives vary depending on their characteristics. In this article, we compare initiatives undertaken in two major counties, Stockholm and Östergötland, and their outcomes. Outcomes include annual drug budget savings while achieving agreed quality as well as increased adherence to prescribing targets and guidance; the latter associated with savings. Appraising these multifaceted reforms can provide guidance to other countries and regions in view of their diversity. Future steps must incorporate measures to improve the utilization of new expensive drugs, which should include horizon scanning and forecasting activities as well as post-launch activities involving monitoring of prescribing and registries. This may well require cooperation with other European countries.

Place, publisher, year, edition, pages
2009. Vol. 9, no 1, 65-83 p.
Keyword [en]
Drug and Therapeutic Committee; Financial incentive; Generic; Healthcare reform; Pharmaceuticals; Pharmacoeconomics; Rational prescribing; Reference price
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-21553DOI: 10.1586/14737167.9.1.65OAI: diva2:241504
Available from: 2009-10-03 Created: 2009-10-02 Last updated: 2011-01-10

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Hoffmann, M.
By organisation
Pharmacology Faculty of Health Sciences
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 54 hits
ReferencesLink to record
Permanent link

Direct link